Replicor 公开了 REP 2139 的抗炎特性

StephenW

Replicor 公开了 REP 2139 的抗炎特性

蒙特利尔，2022 年 10 月 12 日——Replicor Inc. 在 2022 年 10 月 6 日至 7 日在意大利米兰举行的 2022 年 Delta Cure 会议上提供了表明 REP 2139 的广谱抗炎特性的数据（见此处）。

核酸聚合物 (NAP) 的靶标相互作用通过独特的药物界面（见此处）发生，该界面之前显示存在于 1 型病毒糖蛋白、HDAg 和最近的 HSP40 伴侣 DNAJB12 中，这对 SVP 组装至关重要。类似的靶界面也存在于各种促炎细胞因子和趋化因子中，它们驱动 NAP 与这些分子的高亲和力相互作用（参见此处）。

Andrew Vaillant 博士评论说：“NAP 治疗期间宿主介导的转氨酶发作的安全性和耐受性、pegIFN 与 REP 2139 的耐受性提高以及最近在我们的同情使用计划中观察到抗病毒反应之前腹水的快速逆转表明， REP 2139 除了具有抗病毒作用。 NAP 与促炎细胞因子/趋化因子的相互作用表明，伴随着 REP 2139 的肝脏积累具有抗炎活性，这与这些临床观察结果一致。”

关于 Replicor

Replicor 是一家私营生物制药公司，在开发 HBV 和 HDV 治疗方法方面拥有最先进的动物和人类临床数据。公司致力于加速开发针对 HBV 和 HBV/HDV 合并感染患者的有效治疗方法。有关 Replicor 的更多信息，请访问我们的网站 www.replicor.com。

StephenW

Replicor discloses anti-inflammatory properties of REP 2139

MONTREAL, October 12th, 2022 – Replicor Inc., presented data indicating the broad-spectrum anti-inflammatory properties of REP 2139 at the 2022 Delta Cure Meeting held October 6-7, 2022 in Milan, Italy (see here).

Target interaction of nucleic acid polymers (NAPs) occurs via a unique drug interface (see here)  previously shown to be present in type 1 viral glycoproteins, HDAg and most recently the HSP40 chaperone DNAJB12 which is critical for SVP assembly.  Analogous target interfaces are also present in a variety of pro-inflammatory cytokines and chemokines which drive high affinity NAP interactions with these molecules (see here).

Dr. Andrew Vaillant commented, “The safety and tolerability of host mediated transaminase flares during NAP therapy, the improved tolerability of pegIFN with REP 2139 and the recent observations of rapid reversal of ascites prior to antiviral response in our compassionate use program suggests hepatoprotective capabilities of REP 2139 in addition to its antiviral effects.  The interactions of NAPs with pro-inflammatory cytokines / chemokines suggest an anti-inflammatory activity accompanying the liver accumulation of REP 2139 which is consistent with these clinical observations.”

About Replicor

Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.